# Repron Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/repron-therapeutics

- Industry: Biotechnology
- Headquarters: Milan, Italy
- Website: www.reprontherapeutics.com
- Total disclosed funding: $2.2M
- Latest round: Seed (Jun 16, 2023)
- Investors on record: 3

## About

Founded in 2023 and based in Milan, Italy, Repron Therapeutics operates as an epigenetic silencing regulator to intercept and eliminate residual tumor cells at the primary site or micro-metastases in target organs. In June 2023, Repron Therapeutics raised EUR 2 million in seed funding led by Claris Ventures with participation from Consiglio National Research Council(CNR) and San Raffaele Hospital Srl.    

Repron Therapeutics is a developer of a healthcare technology intended to inhibit the activity of oncogenes on the basis of tumor malignancy through the use of engineered synthetic factors. The company aims to provide treatments for solid tumor cases where complete surgical removal is not feasible, and the risk of metastasis or recurrence is high, providing patients with epigenetic silencing regulations to intercept and eliminate residual tumor cells at the primary site or micro-metastases in target organs.

## Funding rounds

- Seed, Jun 16, 2023, $2.2M — Claris Ventures, National Research Council (CNR), San Raffaele Hospital Srl

## Investors

- Claris Ventures (https://capitalatlas.ai/funds/claris-ventures) — Seed
- National Research Council (CNR) — Seed
- San Raffaele Hospital Srl — Seed